Speaker Profile
Ph.D., Co-Founder & CEO, Aikium
Biography
Eswar Iyer is the Co-founder and CEO of Aikium Inc., a therapeutics company pioneering new treatments with Yotta-ML², the world’s first AI-driven trillion-protein wet lab screening platform. With over 100 patents spanning single-cell and spatial multiomics, protein and tissue engineering, hardware, and AI, Eswar has dedicated his career to advancing high-definition biological design and discovery. He completed a postdoc with George Church at Harvard’s Wyss Institute, working on groundbreaking synthetic biology approaches, and holds a PhD from George Mason University. His innovations have driven multiple industry-defining platforms and strategic acquisitions totaling $480 million. Today, Eswar leads Aikium in developing targeted protein therapeutics for diseases with significant unmet needs, focusing on areas where traditional approaches like antibodies and small molecules fall short.
Talk
Worlds First AI-Powered Trillion-Protein Screening: Unlocking the Undruggable Proteome
AI and Data Sciences Showcase:
Aikium
Aikium is revolutionizing therapeutics with Yotta-ML², the world’s first AI-driven trillion-protein screening platform. By unlocking undruggable targets where antibodies and small molecules fail, Aikium pioneers next-generation protein therapeutics for cancer, immune disorders, and beyond—pushing the boundaries of AI-powered drug discovery
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
